Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISA104 synthetic long peptide vaccine in chronic hepatitis B
NL-OMON58977Phase 1Recruiting
- Sponsor
- Erasmus MC
- Start
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 1, single-arm trial of ISA104 in Chronic Hepatitis B (CHB), sponsored by Erasmus MC. Started Nov 2024; status: recruiting.
02
Drugs
ISA104
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NL-OMON58977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58977.